> top > docs > PubMed:10214854 > annotations

PubMed:10214854 JSONTXT

Annnotations TAB JSON ListView MergeView

jnlpba-st-training

Id Subject Object Predicate Lexical cue
T1 64-67 protein denotes Ras
T2 112-125 protein denotes activated Ras
T3 460-471 protein denotes mutated Ras
T4 632-635 protein denotes Ras
T5 663-705 protein denotes major histocompatibility complex molecules
T6 731-740 protein denotes cytokines
T7 742-756 protein denotes growth factors
T8 761-780 protein denotes degradative enzymes
T9 835-846 protein denotes mutated Ras
T10 985-988 protein denotes Ras
T11 1214-1217 protein denotes Ras

pubmed-sentences-benchmark

Id Subject Object Predicate Lexical cue
S1 0-68 Sentence denotes Modulation of the immune response and tumor growth by activated Ras.
S2 69-168 Sentence denotes As a result of its transforming abilities, activated Ras is expressed in a great number of cancers.
S3 169-260 Sentence denotes The ras mutation frequency varies between 95% in pancreatic cancer and 5% in breast cancer.
S4 261-337 Sentence denotes In leukemia, the highest frequency (30%) is found in acute myeloid leukemia.
S5 338-440 Sentence denotes The presence of ras mutations has been correlated with a poor prognosis and negative clinical outcome.
S6 441-606 Sentence denotes This suggests that mutated Ras activates mechanisms, which favor tumor growth, enhance the metastatic capacity of tumors or modulate tumor-specific immune responses.
S7 607-820 Sentence denotes Several new functions of Ras, such as downregulation of major histocompatibility complex molecules, upregulation of certain cytokines, growth factors and degradative enzymes have been uncovered in the last decade.
S8 821-935 Sentence denotes Additionally, mutated Ras can also serve as a primary target for the development of immunotherapy or drug therapy.
S9 936-1108 Sentence denotes This review will discuss the mechanisms by which Ras expressing tumors are able to evade destruction by the immune system and enhance their growth and metastatic potential.
S10 1109-1236 Sentence denotes It will further elaborate on the attempts to develop successful immunotherapy and drug therapy targeting Ras expressing tumors.

genia-medco-coref

Id Subject Object Predicate Lexical cue
C1 38-50 NP denotes tumor growth
C2 54-67 NP denotes activated Ras
C3 84-87 NP denotes its
C4 112-125 NP denotes activated Ras
C5 460-471 NP denotes mutated Ras
C6 482-492 NP denotes mechanisms
C7 494-499 NP denotes which
C8 506-518 NP denotes tumor growth
C9 835-846 NP denotes mutated Ras
C10 936-947 NP denotes This review
C11 961-975 NP denotes the mechanisms
C12 979-984 NP denotes which
C13 985-1006 NP denotes Ras expressing tumors
C14 1070-1075 NP denotes their
C15 1109-1111 NP denotes It
C16 1214-1235 NP denotes Ras expressing tumors
R1 C2 C3 coref-ident activated Ras,its
R2 C3 C2 coref-pron its,activated Ras
R3 C4 C2 coref-ident activated Ras,activated Ras
R4 C7 C6 coref-relat which,mechanisms
R5 C8 C1 coref-ident tumor growth,tumor growth
R6 C9 C5 coref-ident mutated Ras,mutated Ras
R7 C12 C11 coref-relat which,the mechanisms
R8 C14 C13 coref-pron their,Ras expressing tumors
R9 C15 C10 coref-pron It,This review
R10 C16 C13 coref-ident Ras expressing tumors,Ras expressing tumors

GENIAcorpus

Id Subject Object Predicate Lexical cue
T1 18-33 other_name denotes immune response
T2 38-50 other_name denotes tumor growth
T3 64-67 protein_family_or_group denotes Ras
T4 88-110 other_name denotes transforming abilities
T5 112-125 protein_molecule denotes activated Ras
T6 160-167 other_name denotes cancers
T7 218-235 other_name denotes pancreatic cancer
T8 246-259 other_name denotes breast cancer
T9 264-272 other_name denotes leukemia
T10 314-336 other_name denotes acute myeloid leukemia
T11 460-471 protein_molecule denotes mutated Ras
T12 506-518 other_name denotes tumor growth
T13 532-551 other_name denotes metastatic capacity
T14 555-561 tissue denotes tumors
T15 574-605 other_name denotes tumor-specific immune responses
T16 632-635 protein_family_or_group denotes Ras
T17 663-705 protein_family_or_group denotes major histocompatibility complex molecules
T18 731-740 protein_family_or_group denotes cytokines
T19 742-756 protein_family_or_group denotes growth factors
T20 761-780 protein_family_or_group denotes degradative enzymes
T21 835-846 protein_molecule denotes mutated Ras
T22 905-918 other_name denotes immunotherapy
T23 922-934 other_name denotes drug therapy
T24 985-988 protein_family_or_group denotes Ras
T25 1000-1006 tissue denotes tumors
T26 1044-1057 body_part denotes immune system
T27 1087-1107 other_name denotes metastatic potential
T28 1173-1186 other_name denotes immunotherapy
T29 1191-1203 other_name denotes drug therapy
T30 1214-1217 protein_family_or_group denotes Ras
T31 1229-1235 tissue denotes tumors

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 160-167 HP_0002664 denotes cancers
T2 218-235 HP_0002894 denotes pancreatic cancer
T3 229-235 HP_0002664 denotes cancer
T4 246-259 HP_0003002 denotes breast cancer
T5 246-259 HP_0100013 denotes breast cancer
T6 253-259 HP_0002664 denotes cancer
T7 264-272 HP_0001909 denotes leukemia
T8 314-336 HP_0004808 denotes acute myeloid leukemia
T9 320-336 HP_0012324 denotes myeloid leukemia
T10 328-336 HP_0001909 denotes leukemia
T11 506-511 HP_0002664 denotes tumor
T12 555-561 HP_0002664 denotes tumors
T13 574-579 HP_0002664 denotes tumor
T14 1000-1006 HP_0002664 denotes tumors
T15 1229-1235 HP_0002664 denotes tumors